Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no study data or page functionality appears to be altered.SummaryDifference0.0%

- Check22 days agoChange DetectedAdded Primary peritoneal carcinoma to the conditions, introduced a Resources section with the Genetic and Rare Diseases Information Center, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check38 days agoChange DetectedAdded Show glossary and Hide glossary controls, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.3%

- Check45 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check74 days agoChange DetectedLocations are reorganized under a new consolidated 'Locations' section, adding Ontario and Quebec sites and removing the previous separate state/location blocks.SummaryDifference1%

- Check97 days agoChange DetectedOnly the revision tag changed from v3.2.0 to v3.3.2; no core content appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.